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Abstract We investigated the relationship between the
functional insertion/deletion (I/D) polymorphism in the
angiotensin-converting enzyme (ACE) gene and the risk of
nicotine dependence in Croatian schizophrenia patients.
We also tested whether interactions between ACE-I/D
polymorphism and smoking status affected the clinical
psychopathology findings in patients as measured using
Positive and Negative Symptom Scale (PANSS) scores.
Polymerase chain reaction analysis was used to genotype
267 chronically ill schizophrenia patients (140 males/127
females). There were no significant differences in the dis-
tribution of ACE genotypes and alleles in male or female
schizophrenia patients who were stratified based on their
smoking status. However, there was a trend toward a dif-
ference in the ACE genotype distribution in female
smokers vs. nonsmokers (v2 = 5.13, p = 0.077) that was
due mainly to the significant overrepresentation of ACE-ID
heterozygous genotypes in female smokers compared to
nonsmokers (62.3 vs. 42.0%, p = 0.025). ACE-ID
heterozygous females had about a twofold higher smoking
risk than ACE-II and ACE-DD homozygous carriers
(OR = 2.29, 95% CI 1.1–4.7, p = 0.026). We observed no
contribution of the ACE genotype-smoking interaction to
PANSS psychopathology. This is the first study to inves-
tigate the possible association between ACE-I/D poly-
morphism and nicotine dependence in schizophrenia. Our
results suggest that the ACE-I/D polymorphism may be
relevant in determining the risk of nicotine dependence in
female patients with schizophrenia while the ACE geno-
type-smoking interaction does not contribute to the clinical
expression of schizophrenia.
Keywords Angiotensin-converting enzyme gene  Positive
and Negative Syndrome Scale  Schizophrenia  Smoking
Introduction
The pleasurable effects of nicotine, the primary addictive
component of tobacco smoke, are thought to be mediated
by nicotine’s ability to stimulate brain mesolimbic dopa-
mine neurons. By acting on presynaptic nicotinic cholin-
ergic receptors, nicotine is suggested to increase dopamine
release and reuptake; in addition, by decreasing the activity
of the monoamine oxidase enzyme, nicotine may inhibit
dopamine degradation (Drew et al. 2000; Fowler et al.
2003; Iasevoli et al. 2013; Novak et al. 2010; Sagud et al.
2009; Severance et al. 2009). A worldwide meta-analysis
revealed that the smoking rate in schizophrenia subjects is
threefold greater than among healthy individuals and that
the incidence of smoking is twofold higher than in subjects
with other psychiatric illnesses (de Leon and Diaz 2005;
Levin and Rezvani 2007; Zhang et al. 2012).
The etiology of such high rates of smoking in
schizophrenia is not well understood. According to the self-
medication hypothesis, smoking may have a beneficial
effect in schizophrenia; by restoring dopaminergic
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transmission via central effects of nicotine on dopaminer-
gic system, cigarette smoking may ameliorate cognitive
deficits and may also decrease the severity of negative
symptoms and the extrapyramidal side effects of antipsy-
chotic medications that block postsynaptic dopamine D2
receptors (Laruelle et al. 2003; Sagud et al. 2009; Zhang
et al. 2015; Winterer 2010). However, nicotine has been
shown to increase the metabolism of antipsychotic drugs
by approximately one-third, through the induced activity of
the cytochrome family of enzymes (Misiak et al. 2015;
Sagud et al. 2009; Winterer 2010; Zevin and Benowitz
1999). Thus, patients who smoke may be easily under-
treated with antipsychotics; this under-medication may
partially explain why smokers with schizophrenia have
higher number of hospitalizations and more positive
symptoms during acute episodes (Williams and Ziedonis
2004; Winterer 2010). Finally, the genetic hypothesis
proposes that there is a shared genetic vulnerability i.e. that
some genes, especially those in the dopamine signaling
pathways, such as dopamine receptor D2 (DRD2), alpha7
nicotinic acetylcholine receptor (CHRNA7), and brain-
derived neurotrophic factor (BDNF), might exert pleio-
tropic effects, contributing to both nicotine dependence and
schizophrenia (de Leon and Diaz 2012; de Luca et al. 2004;
Kelly and McCreadie 2000; Yoshimasu and Kiyohara
2003; Zhang et al. 2015).
Angiotensin-converting enzyme (ACE) catalyzes the
conversion of angiotensin I to angiotensin II in the renin-
angiotensin system (RAS) and inactivates bradykinin via
the kinin-kallikrein system (Nawaz and Hasnain 2008;
Song and Lee 2015). Several lines of evidence suggest that
RAS, beyond its classical function in mediating the regu-
lation of blood pressure, might also act as an important
determinant in the etiology of conditions involving dopa-
mine, such as substance addiction and psychiatric disor-
ders, by influencing dopaminergic signaling (Jenkins et al.
1996, 1997; Obata et al. 2008). Notably, the neurotrans-
mitter angiotensin II interacts with dopamine in mesocor-
ticolimbic areas, and ACE modulates dopamine turnover in
the rat striatum (Jenkins et al. 1996, 1997). In addition,
there is decreased dopamine release in the rat striatum in
response to captopril and enalaprilat, antihypertensive
drugs that inhibit ACE activity (Obata et al. 2008).
To date, several reports have described significantly
increased ACE activity in the brain as well as in various
peripheral tissues (serum, plasma, etc.) of individuals with
schizophrenia (Baskan et al. 2010; Gadelha et al. 2015;
Wahlbeck et al. 1993). The most studied RAS-related
polymorphic variant, a functional 287-base pair insertion/
deletion (I/D) fragment that represents a polymorphism in
intron 16 of the ACE gene, accounts for approximately
50% of the ACE levels (Rigat et al. 1990). The influence of
the ACE-I/D polymorphism on the etiology of
schizophrenia has been extensively investigated (Hui et al.
2014; Nadalin et al. 2012; Song and Lee 2015), but the
results have been conflicting. Specifically, there is evidence
of an association between the ACE-I/D polymorphism and
elevated schizophrenia risk in Spanish and Turkish popu-
lations and in women with schizophrenia in the Iranian
population (Crescenti et al. 2009; Kucukali et al. 2010;
Mazaheri and Saadat 2015). Nevertheless, a meta-analysis
of eight studies conducted mostly in European and Asian
populations showed no significant associations between the
ACE-I/D polymorphic variant and elevated schizophrenia
risk (Song and Lee 2015). We recently observed that ACE-
I/D polymorphism influenced the clinical expression of
schizophrenia as measured via the Positive and Negative
Syndrome Scale (PANSS) in a Croatian population
(Nadalin et al. 2012). Specifically, we found that patients
carrying the D allele in their ACE genotype (ACE-DD
homozygous and ACE-ID heterozygous genotypes) had
significantly higher negative and general PANSS scores
compared to patients who were ACE-II homozygous. In
addition, after adjustment for sex, we also observed that the
presence of the D allele in the ACE genotype contributed to
increased general symptom severity in men with
schizophrenia.
Only a few studies have investigated a possible associ-
ation between the ACE-I/D polymorphism and nicotine
dependence (Baghai et al. 2008; Hubacek et al.
2001, 2004). While German ACE-DD homozygous indi-
viduals suffering from depression have a significantly
higher risk of being smokers (Baghai et al. 2008), studies
of healthy subjects in the Czech Republic and in Germany
found no associations between ACE-I/D polymorphism
and smoking risk (Baghai et al. 2008; Hubacek et al. 2004).
Furthermore, the ACE-I/D polymorphism might influence
smoking severity. Specifically, the ACE-DD homozygous
genotype was associated with higher daily cigarette con-
sumption in patients with depression as well as with a
smoking history of a greater number of pack-years in
healthy individuals in a German population (Baghai et al.
2008).
To the best of our knowledge, no studies have investi-
gated a possible association between ACE-I/D polymor-
phism and nicotine dependence in schizophrenia. Based on
the elevated smoking rate that is consistently observed in
schizophrenia patients (de Leon and Diaz 2005; Zhang
et al. 2012) and on the possible relevance of the ACE gene
in schizophrenia and nicotine dependence via dopaminer-
gic signaling (Obata et al. 2008; Song and Lee 2015), we
investigated whether the risk for nicotine dependence in
schizophrenia patients was associated with the ACE-I/D
polymorphic variant. There is evidence suggesting that
smoking might influence the clinical expression of
schizophrenia (Xu et al. 2014; Yee et al. 2015), and we
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found previously that the ACE-I/D polymorphism impacts
schizophrenia severity (Nadalin et al. 2012). Accordingly,
we further hypothesized that an interaction between
smoking and ACE-I/D polymorphism might affect PANSS
psychopathology scores in a group of patients with
schizophrenia. Because of sex-specific differences in the
effects of the ACE-I/D polymorphism in various diseases
and conditions (Avila-Vanzzini et al. 2015; Higaki et al.
2000), including schizophrenia (Mazaheri and Saadat
2015; Nadalin et al. 2012, 2015), and because of obser-
vations of sex-gene interactions in the risk of nicotine
dependence (Beuten et al. 2006; Nedic et al. 2010; Tochigi
et al. 2007; Nadalin et al. 2016), we performed all analyses
separately for male and female patients.
Patients and methods
Study participants
Our study group included 267 chronically ill schizophrenia
in-patients who were treated at the Department of Psychi-
atry in the Clinical Hospital Center in Rijeka, Croatia
(n = 179) or at the Psychiatric Hospital in Rab, Croatia
(n = 88) due to an acute exacerbation of schizophrenia
symptoms. Table 1 shows the patients’ demographic and
clinical characteristics. Their diagnoses were assessed by at
least two psychiatrists according to the Diagnostic and
Statistical Manual of Mental Disorders (DSM-IV) criteria
using structured clinical interviews. PANSS psy-
chopathology evaluation was performed at the time of each
patient’s last admission during an acute state of the illness
that required hospitalization.
All patients were treated with a stable antipsychotic
medication regimen for at least 12 months before they
entered the study. Antipsychotic polytherapy was used in
two-thirds of the patients, while one-third of them received
monotherapy. The patients received the following drugs:
risperidone (n = 90), clozapine (n = 84), olanzapine
(n = 81), quetiapine (n = 71), haloperidole (n = 42),
fluphenazine (n = 37), paliperidone (n = 34), aripiprazole
(n = 27), levomepromazine (n = 25), ziprasidone
(n = 23), sulpiride (n = 21), and amisulpride (n = 9). The
antipsychotic promazine was also prescribed to many
patients (n = 114), usually in smaller doses (75–150 mg
per day), when anxiolytic or hypnotic drugs, such as ben-
zodiazepines or barbiturates, were not sufficiently effec-
tive. The mean antipsychotic dose (converted to
chlorpromazine equivalents) was 550 ± 250 mg per day
(Woods 2003).
The psychiatrists obtained information about the
patients’ smoking status via a questionnaire. Smokers were
defined as individuals who smoked more than one cigarette
each day who had smoked for more than one year. Non-
smokers were defined as those who had smoked fewer than
100 cigarettes during their lifetime. Former smokers were
characterized as individuals who had previously smoked
more than one cigarette each day but who had quit smoking
more than one year before the questionnaire was filled out
(de Leon and Diaz 2005; Guo et al. 2007). Quitters and ex-
smokers were excluded from the study.
All clinical and laboratory investigations were con-
ducted in accordance with the ethical standards of the latest
version of the Declaration of Helsinki. After the study’s
purpose and methods had been described, the patients
provided written informed consent to participate in the
study, which was approved by the Ethics Committee of the
School of Medicine, University of Rijeka, Croatia.
Genotyping
Genomic DNA was extracted from whole blood using the
FlexiGene DNA kit 250 (QIAGEN GmbH, Hilden, Ger-
many) according to the manufacturer’s instructions. Poly-
merase chain reaction (PCR) based genotyping was
performed in the Laboratory for Molecular Genetics
(Department of Biology and Medical Genetics, School of
Medicine, Rijeka) using protocols that were described
previously (Rigat et al. 1990). To exclude mistyping of the
ACE-ID heterozygotes as ACE-DD homozygotes, all
Table 1 Characteristics of the
schizophrenia patients in this
study
Males (n = 140) Females (n = 127)
Age, years 40.6 ± 12.0 42.9 ± 11.8
Age at first hospitalization 26.2 ± 7.6 27.6 ± 8.2
PANSS positive symptom score 26.6 ± 5.3 25.2 ± 5.6
PANSS negative symptom score 29.5 ± 6.4 28.4 ± 6.9
PANSS general psychopathology scorea 53.1 ± 7.8 50.7 ± 7.9
PANSS total scoreb 109.2 ± 15.1 104.3 ± 15.8
Smokers/nonsmokers 99/41 77/50
PANSS Positive and Negative Syndrome Scale
Males vs. females: a F = 4.00, p = 0.047; b F = 4.35, p = 0.039
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ACE-DD genotypes were confirmed using insertion-
specific PCR (Shanmugam et al. 1993).
Statistical analysis
The ACE genotype and allele distributions among smokers
and nonsmokers, as well as the observed and expected
genotype proportions according to the Hardy–Weinberg
equilibrium, were compared by the Chi-square (v2) test.
Odds ratios (OR) and 95% confidence intervals (CIs) were
used to examine the strength of the association between the
ACE-ID heterozygous genotype and the risk for being a
smoker among female patients. The factorial analysis of
variance (ANOVA) was used to test the possible interac-
tion between ACE genotype and smoking status on posi-
tive, negative, general, and total PANSS psychopathology
scores. Probability (p) values less than 0.05 (p\ 0.05)
were considered statistically significant. All statistical
analyses were conducted using Statistica for Windows,
version 12.
Results
The smoking rate was higher for both male and female
schizophrenia patients compared to the rate in the general
population, with about two-thirds of the patients classified
as smokers (Table 1). Interestingly, we found that the
prevalence of nicotine dependence did not differ signifi-
cantly with respect to sex (p[ 0.05). Table 2 shows the
allele and genotype frequencies for the ACE-I/D poly-
morphism according to patient smoking status. The statis-
tical power of our study was 100% for detecting a 1.5-fold
increase in the ACE-D allele frequency and 98% for
detecting a 1.5-fold increase in the ACE-I allele frequency.
The ACE genotype distributions in male and female
patients, in male smokers and nonsmokers, and in female
nonsmokers were all consistent with the Hardy–Weinberg
equilibrium (p[ 0.05 for all). However, the ACE genotype
distribution in female smokers deviated slightly from the
Hardy–Weinberg equilibrium due to an excess of ACE
heterozygous (ID) genotypes (v2 = 5.99, p = 0.024). The
allele and genotype frequencies of the ACE-I/D polymor-
phism were similar to those we reported in our previous
studies (Nadalin et al. 2012, 2015) and were not different
from those observed in the European population (http://
www.ncbi.nlm.nih.gov/snp/?term=rs1799752). Moreover,
no significant differences were found in the ACE genotype
and allele distributions between groups of male and female
schizophrenia patients (p[ 0.05). We did not find any
significant differences in the distribution of the ACE
genotypes and alleles in either male or female patients who
were stratified according to their smoking status (Table 2).
However, we observed a trend towards a difference in the
ACE genotype distribution in female smokers compared to
female nonsmokers (v2 = 5.13, p = 0.077) that was due
mainly to significant overrepresentation of the ACE-ID
heterozygous genotype in female smokers compared with
nonsmokers (62.3 vs. 42.0%, p = 0.025). Furthermore, the
ACE-heterozygous females (ID) had about a twofold
Table 2 The frequency of ACE
genotypes and alleles according
to smoking statusa
Males
Smokers (n = 99) Nonsmokers (n = 41)
DD 32 (32.3) 11 (26.8) v2 = 1.43, df = 2, p = 0.495
ID 45 (45.5) 17 (41.5)
II 22 (22.2) 13 (31.7)
D allele 109 (55.1) 39 (47.6) v2 = 1.31, df = 1, p = 0.253
I allele 89 (44.9) 43 (52.4)
Females
Smokers (n = 77) Nonsmokers (n = 50)
DD 18 (23.4) 19 (38.0) v2 = 5.13, df = 2, p = 0.077
ID 48 (62.3) 21 (42.0)
II 11 (14.3) 10 (20.0)
ID vs. II ? DD OR = 2.29, 95% CI 1.1–4.7, p = 0.026
D allele 84 (54.5) 59 (59.0) v2 = 0.49, df = 1, p = 0.484
I allele 70 (45.5) 41 (41.0)
ACE angiotensin-converting enzyme, CI confidence interval, OR odds ratio
a Data are reported as n (%)
p value less than 0.05 were considered statistically significant
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higher risk of becoming smokers than the ACE-II and
ACE-DD homozygous carriers (OR = 2.29, 95% CI
1.1–4.7, p = 0.026).
We also investigated whether the ACE genotype inter-
acted with patient smoking status to contribute to the
clinical expression of schizophrenia, which was measured
using PANSS scores. We found no ACE genotype-smoking
interaction with the PANSS scores for either male or
female patients (p[ 0.05 for both; Supplementary
Table 1).
Discussion and conclusions
Due to their high smoking rate, schizophrenia patients
represent a particularly interesting model group for study-
ing the etiology of nicotine dependence (de Leon and Diaz
2005; Levin and Rezvani 2007). The ACE-I/D polymor-
phic variant has been intensively investigated in
schizophrenia (Hui et al. 2014; Nadalin et al. 2012; Song
and Lee 2015) and was associated with schizophrenia
severity in our recent study (Nadalin et al. 2012). Here we
investigated whether the ACE-I/D polymorphism might
influence the risk of nicotine dependence in Croatian
schizophrenia patients and whether an interaction between
this variant and smoking status might contribute to baseline
psychopathology data as measured using PANSS scores.
Functional analysis of the ACE-I/D polymorphism,
which was first described over two decades ago, indicates
that the homozygous ACE-DD genotype is associated with
tissue and plasma enzyme levels that are almost twice as
high as those in subjects with the homozygous ACE-II
genotype (Rigat et al. 1990). In line with this, we initially
speculated that patients with the ACE-DD genotype might
release dopamine at higher levels in their brains and might
consequently be more vulnerable to developing nicotine
dependence. However, our data indicated a greater risk for
smoking in female patients who were heterozygous for the
ACE genotype (ID), which argues against this hypothesis
(Table 2). Moreover, our results disagree with previous
reports about the ACE-I/D polymorphism and nicotine
dependence: no associations between smoking and ACE-I/
D polymorphism in healthy individuals from the Czech
Republic and Germany were observed, and there were
positive associations between the risk of being a smoker
and ACE-DD homozygosity among patients suffering from
depression in a German population (Baghai et al. 2008;
Hubacek et al. 2004). Furthermore, although evidence
suggests that nicotine as well as ACE and/or angiotensin II
potentiate dopamine release in same signaling pathway i.e.
the mesolimbic dopaminergic reward pathway (Jenkins
et al. 1996, 1997; Sagud et al. 2009), we found that the
ACE genotype-smoking interaction had no significant
influence on PANSS psychopathology scores (Supple-
mentary Table 1).
Interestingly, our analyses of the possible association
between ACE-I/D polymorphism alone and PANSS psy-
chopathology scores did not support the results of our
previous study (Nadalin et al. 2012), since this study found
that the ACE-I/D variant had no significant impact on any
of the PANSS scores (data not shown). Nevertheless, it
should be noted that novel findings likely reflect the rather
complex relationship between ACE genotype and ACE
levels in schizophrenia patients (Baskan et al. 2010;
Gadelha et al. 2015). For instance, the study carried out by
Baskan et al. (2010) yielded unexpected results in that they
found that there were no significant differences in serum
ACE levels based on different ACE genotypes in a patient
group. In addition, a recent study by Gadelha et al. (2015)
calculated delta-ACE values in schizophrenia patients by
subtracting the mean ACE activity value in control subjects
with particular genotypes from the observed plasma ACE
activity value in schizophrenia patients with the same
genotype. Their findings suggest that delta-ACE values are
much better predictors of schizophrenia diagnosis than
either ACE dichotomized values (high/low) or ACE-I/D
polymorphism genotype alone.
Several findings could account for the gender specific
differences in the ACE-I/D polymorphism observed in this
study (Gallagher et al. 1999; Sanada et al. 2001; Sumino
et al. 2003). It has been shown that estrogen replacement
therapy in postmenopausal women may result in the
genotype-associated decrease in ACE activity: a significant
decrease in plasma ACE activity was observed either in
women with the ACE-ID and ACE-II genotypes (Sanada
et al. 2001), or in those with the ACE-ID and ACE-DD
genotypes (Sumino et al. 2003). Moreover, there is also
evidence that estrogen may influence dopaminergic neu-
rotransmission, since it has been observed that estrogen
treatment reduces dopamine receptor D2 levels in several
rat brain regions (Chavez et al. 2010).
This study has several limitations. Our sample was rel-
atively small, so there is a possibility that some minor
effects were not detected. In addition, the study only
included patients who were hospitalized, and, therefore,
they had more severe psychopathology and longer illness
duration than typical psychotic outpatients or first-episo-
de/drug-naı¨ve schizophrenia patients. Moreover, the cur-
rent sample lacked a healthy control group, and data
regarding smoking status were based exclusively on self-
reporting. Finally, all patients were under antipsychotic
treatment; there is evidence that antipsychotic medications
may reduce or increase ACE expression/activity (Beck-
mann et al. 1984; Wahlbeck et al. 1993, 1998).
In conclusion, our results suggest that the ACE-I/D
polymorphism may be relevant in determining the risk of
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nicotine dependence in women with schizophrenia. They
also indicate that the ACE genotype-smoking interaction
has no significant influence on the clinical expression of
schizophrenia in either male or female patients. According
to the studies investigating an association between the
ACE-I/D polymorphism and nicotine dependence among
healthy controls and patients with depression, our findings
indicated that the mechanism by which ACE-I/D poly-
morphism contributes to the risk of nicotine dependence in
schizophrenia may be different than in other diseases and
conditions (Baghai et al. 2008; Hubacek et al. 2004).
Furthermore, there was a weak but significant overrepre-
sentation of ACE-ID heterozygous genotypes in female
smokers vs. nonsmokers (62.3 vs. 42.0%, p\ 0.05), which
may suggest that intermediate ACE levels (rather than
decreased or increased ACE levels) are responsible for the
greater risk of nicotine dependence in schizophrenia.
Although our sample size was small, the strength of this
study is in that it was conducted in a tightly defined, severe
schizophrenia cohort. However, larger studies, as well as
studies that include participants with other neuropsychi-
atric disorders, plus an assessment of nicotine dependence
that uses more specific methods (e.g. the Fagerstrom test
for nicotine dependence, ‘‘pack-year’’ smoking history,
etc.) are needed to verify our findings. It also seems
important to clarify the underlying molecular mechanisms
that may link the ACE-I/D polymorphic variant with
dopaminergic signaling. Another issue that should be
considered is that both ACE and angiotensin II have other
potential substrates, some of which influence dopaminergic
neurotransmission and are proposed to be associated with
schizophrenia, such as substance P and neurotensin (Ari-
nami et al. 1996; Azmi et al. 2006; Binder et al. 2001;
Gadelha et al. 2015; Krasnova et al. 2000).
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